Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.74 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.74 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.74 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24880 | 1.00 | OPRD1 (0.74) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL29359245 | 1.00 | OPRD1 (0.74) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL678993 | 1.00 | OPRD1 (0.74) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL15249248 | 1.00 | OPRD1 (0.74) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Hydrochloric Acid SCHEMBL31058090 | 0.99 | OPRD1 (0.73) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Propionic Acid SCHEMBL28993771 | 0.95 | OPRD1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL16866229 | 0.95 | OPRM1 (0.66) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL23673341 | 0.91 | OPRD1 (0.71) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL31298539 | 0.91 | OPRM1 (0.76) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL27557540 | 0.90 | OPRD1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116419755-A | Ophthalmic implant containing active agent | 视觉治疗股份有限公司 | 2023-07-11 | — | — | CN | claimed |
| CN-110831575-A | Pharmaceutical preparation | 卡里亚制药控股有限公司 | 2020-02-21 | — | — | CN | claimed |
| CN-109069419-A | Abuse resistant drugs composition | G.L.制药有限责任公司 | 2018-12-21 | — | — | CN | claimed |
| CN-102159193-B | Pharmaceutical dosage form comprising poly (-caprolactone) | PURDUE PHARMA L.P. (US) | 2015-09-16 | — | — | CN | claimed |
| CN-104010630-A | Pharmaceutical dosage form comprising poly (epsilon-caprolactone) and polyoxyethylene | PURDUE PHARMA LP | 2014-08-27 | — | — | CN | claimed |
| US-20140193490-A1 | ORAL DOSAGE FORMS WITH THERAPEUTICALLY ACTIVE AGENTS IN CONTROLLED RELEASE CORES AND IMMEDIATE RELEASE GELATIN CAPSULE COATS | PAIN THERAPEUTICS, INC. (US) | 2014-07-10 | — | — | US | claimed |
| US-20130344143-A1 | FORMULATIONS OF NONOPIOID AND CONFINED OPIOID ANALGESICS | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-12-26 | — | — | US | claimed |
| CN-103402499-A | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans | MALLINCKRODT LLC | 2013-11-20 | — | — | CN | claimed |
| EP-2612553-A1 | Compositions and Methods for Prophylaxis and Treatment of Addictions | Omeros Corporation (US) | 2013-07-10 | — | — | EP | claimed |
| CN-1809340-B | Pharmaceutical products | EURO CELTIQUE SA | 2013-07-10 | — | — | CN | claimed |
| CN-1627938-A | Pharmaceutical dosage form for transmucosal delivery | PHARMACIA CORP (US) | 2005-06-15 | — | — | CN | claimed |
| CN-1531431-A | Prevention of addiction in pain management | ��³�˹��Ŀ�ѧЭ�� | 2004-09-22 | — | — | CN | claimed |
| CN-1134253-C | Oral sustained release opioid formulations and methods of making same | ŷ�����ǹɷ�����˾ | 2004-01-14 | — | — | CN | claimed |
| CN-1450883-A | Transdermal delivery system for alkaloids of aconitum species | XEL HERBACEUTICALS (US) | 2003-10-22 | — | — | CN | claimed |
| CN-1356981-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-07-03 | — | — | CN | claimed |
| CN-1069544-C | Thebaica giving-up vaccinum for man | KUNMING BIOLOG TECH ENGINEERIN (CN) | 2001-08-15 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| CN-1278158-A | Synergistic analgestic combination of opioid analgsic and cyclooxygenase-2 | EURO CELTIQUE SA (LU) | 2000-12-27 | — | — | CN | claimed |
| CN-1196955-A | Thebaica giving-up vaccinum for man | KUNMING BIOLOG TECH ENGINEERIN (CN) | 1998-10-28 | — | — | CN | claimed |
| CN-1130352-A | Method for relieving pain by orally administering 24-hour sustained-release opioid dosage form capable of rapidly increasing initial blood concentration of patient | EURO CELTIQUE SA (LU) | 1996-09-04 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130344143-A1 | FORMULATIONS OF NONOPIOID AND CONFINED OPIOID ANALGESICS | OPRK1, OPRL1, SIGMAR1 | OPRD1 4/4885OPRM1 6/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.